Kilambi News
Tuesday, November 17, 2026

Seawolf launches with $100 million for non-viral DNA therapies

Life Sciences Monday, November 16, 2026 - Updated Nov 16, 2026 05:41

Seawolf Therapeutics emerged from stealth with $100 million in financing to develop DNA-based therapies delivered by lipid nanoparticles rather than viruses, alongside a Sanofi collaboration worth up to $1.2 billion in milestone payments.

Why it matters: Non-viral delivery that can be redosed is one of gene therapy's open problems; a $100 million syndicate including Eli Lilly, CRISPR Therapeutics and Novartis's venture arm, plus a Sanofi licence, is a notable industry bet on Seawolf's TRIDENT platform.

Data as of BioPharma Dive report of November 16, 2026, read in full; Endpoints News and STAT carried the same launch and financing figures the same day. Developing item.

Seawolf Therapeutics, a San Diego company, emerged from stealth on November 16 with $100 million in financing to develop DNA-based therapies delivered into cells by lipid nanoparticles rather than viruses. Founding investor Versant Ventures led the seed funding and joined a Series A alongside MPM BioImpact and Alexandria Venture Investments, with Eli Lilly, CRISPR Therapeutics and Novartis’s venture arm also contributing.

Seawolf also disclosed a multi-target research collaboration and exclusive licence agreement with Sanofi focused on bleeding disorders and other indications, worth up to $1.2 billion in milestone payments plus tiered royalties. Its TRIDENT platform wraps engineered DNA in a proprietary lipid nanoparticle designed to reach the cell nucleus without triggering an immune response, which the company says allows repeat dosing that viral delivery systems cannot match; its lead programme targets metabolic diseases.

Sources

  1. Big-name investors pour $100M into DNA therapeutics developer Seawolf - BioPharma Dive - 2026-11-16
  2. Seawolf launches with $100M to make non-viral gene therapies - Endpoints News - 2026-11-16